Spark Therapeutics (ONCE) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Wall Street stocks close lower on higher Treasury yields, rate expectations
- Powell says recent inflation data point to need to keep rates higher for longer
- United Airlines maintains forecast after Q1 results top Wall Street estimates
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- Bank of America profit hurt by losses on credit cards, office loans
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
Spark Therapeutics Reports Second Quarter 2016 Financial Results and Recent Business Highlights
August 10, 2016 7:30 AM EDTUpdated timing of the completed BLA submission for voretigene neparvovec
Earlier today, released additional positive data from the pivotal Phase 3 trial of voretigene neparvovec
Reported positive preliminary safety and efficacy from the Phase 1/2 clinical trial of SPK-9001 in hemophilia
PHILADELPHIA, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE) today announced financial results for the quarter ended June 30, 2016 and updated investors on its progress.
During the last several months, we have made significant progress advancing our clinical portfolio of AAV gene therapy... More
